Curatis on track: submission of orphan drug designation application in the US for lead product candidate
Liestal, Switzerland, 24 May 2024: Curatis Holding AG (CURN.SW), previously Kinarus Therapeutics Holding AG (together with its subsidiaries “Curatis Group”, or the “Company”), a SIX Swiss Exchange listed specialty pharmaceutical and therapeutic drug development company focused on orphan and ultra-orphan indications today published its annual report for FY2023. The audited consolidated FY2023 financial statements and the audited statutory FY2023 financial statements of the Company, together the audited “FY2023 Financial Statements”, had already been published on 17 April 2024. Both, Kinarus Therapeutics Holding AG and its 100% subsidiary, Kinarus AG in Liquidation had filed for bankruptcy in October 2023, but on 5 February 2024, bankruptcy of Kinarus Therapeutics Holding AG was revoked by the competent courts of Basel-Stadt to pave the way for the business combination of Kinarus Therapeutics Holding AG and Curatis AG, a Basel-Landschaft incorporated specialty medicine distribution and drug development company (the “Business Combination”), which was completed on 26 April 2024. Kinarus AG in Liquidation remains in liquidation. The 2023 Annual Report of Kinarus Group therefore does not provide a comprehensive and transparent picture on the effective situation of the Company today after the completion of the Business Combination of Kinarus Therapeutics Holding AG with Curatis AG.
Basel, Switzerland, July 12, 2023 €“ Kinarus Therapeutics Holding AG (€œKinarus€) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and...
Basel, Switzerland, May 10, 2023 â“ Kinarus Therapeutics Holding AG (âœKinarusâ) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and...
Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announced that it has engaged with Great Health Companion Group Ltd (GHCG), a subsidiary of Hakim Unique Group, a global conglomerate from China, to explore partnering options to initiate phase 2 testing of KIN001 to treat wet age-related macular degeneration (wAMD) and idiopathic pulmonary fibrosis (IPF). In addition, Kinarus and GHCG will explore further business opportunities which may include licensing or strategic partnerships. Kinarus sees multiple opportunities for KIN001 in indications with high unmet need are well-matchedto the Chinese market.